Telephone
61.3.9093.3855
Address
North Melbourne Suite 401 55 Flemington Road Melbourne, Victoria (VIC) 3051
Description
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 8.2 - 20.76
Trade Value (12mth)
AU$4,338,243.00
1 week
-6.29%
1 month
-2.52%
YTD
73.02%
1 year
57.83%
All time high
20.76
EPS 3 yr Growth
-109.30%
EBITDA Margin
11.60%
Operating Cashflow
$24m
Free Cash Flow Return
18.80%
ROIC
4.10%
Interest Coverage
59.00
Quick Ratio
1.30
Shares on Issue (Fully Dilluted)
332m
HALO Sector
Healthcare
Next Company Report Date
19-Feb-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
3.36
Date | Announcements |
---|---|
30 August 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
28 August 24 |
Telix Submits NDA for TLX101-CDx Brain Cancer Imaging Agent
×
Telix Submits NDA for TLX101-CDx Brain Cancer Imaging Agent |
27 August 24 |
Telix Reorganisation to Deliver on Strategic Priorities
×
Telix Reorganisation to Deliver on Strategic Priorities |
22 August 24 |
Telix 1H 2024 Appendix 4D and Interim Report
×
Telix 1H 2024 Appendix 4D and Interim Report |
22 August 24 |
Telix 1H 2024 Results Release
×
Telix 1H 2024 Results Release |
22 August 24 |
Telix 1H 2024 Results Presentation
×
Telix 1H 2024 Results Presentation |
22 August 24 |
Securities Dealing Policy - Updated
×
Securities Dealing Policy - Updated |
22 August 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
21 August 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
14 August 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
13 August 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
13 August 24 |
Telix 2024 Half-Year Results Investor Webcast Notification
×
Telix 2024 Half-Year Results Investor Webcast Notification |
07 August 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
05 August 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
31 July 24 |
BLA Filing Update for Renal Cancer Imaging Agent TLX250-CDx
×
BLA Filing Update for Renal Cancer Imaging Agent TLX250-CDx |
31 July 24 |
Investor Conference Call - TLX250-CDx BLA Filing Update
×
Investor Conference Call - TLX250-CDx BLA Filing Update |
30 July 24 |
Convertible Bond Cleansing Notice
×
Convertible Bond Cleansing Notice |
30 July 24 |
Telix Completes A$650 Million of Convertible Bonds
×
Telix Completes A$650 Million of Convertible Bonds |
30 July 24 |
Appendix 3G
×
Appendix 3G |
29 July 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
26 July 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
24 July 24 |
Telix Successfully Prices A$650M Convertible Bonds
×
Telix Successfully Prices A$650M Convertible Bonds |
24 July 24 |
Appendix 3B
×
Appendix 3B |
24 July 24 |
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
×
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent |
23 July 24 |
Telix Announces A$600 Million Convertible Bonds Offering
×
Telix Announces A$600 Million Convertible Bonds Offering |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.